Themis Medicare Limited has informed the Exchange regarding Appointment of Ms. Neha Thakore as Independent Director of the company w.e.f. August 01, 2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare reported a sharp swing to a loss in Q1 FY26, with standalone net loss of Rs. 15.37 crore versus a profit of Rs. 18.71 crore in the same quarter last year, as revenue from operations fell about 21% to Rs. 97.58 crore. The company also booked an exceptional item of Rs. 1.29 crore linked to the strike-off of its UK wholly-owned subsidiary Carpo Medicals Limited. The board approved the appointment of Ms. Neha Thakore as an Additional Non-Executive Woman Independent Director for five years, and Mr. Viraj Save as Executive President – Sales & Marketing as Senior Management Personnel. The previously announced scheme of amalgamation with Gujarat Themis Biosyn Limited (GTBL) has been mutually withdrawn, and the company will continue to focus on its domestic formulations business. A record date of September 5, 2025 has been fixed for the final dividend for FY ended March 31, 2025.
Weak quarterly earnings, a scrapped merger and a one-time write-off on the UK subsidiary are negative for near-term sentiment, but the board strengthening with a new independent director and experienced sales head is a mild positive for long-term governance and execution.